IDH2 and acute myeloid leukemia: The combination of Enasidenib with intensive induction and consolidation chemotherapy was explored in 93 fit IDH2MUT AML patients, showing that it was well tolerated and was associated with a CR + CRi rate of 77%, with 23% of the patients achieving IDH2 mutation clearance [32].